Oxford Biomedica and Homology Medicines launch US business as John Dawson retires

28 January 2022

UK gene and cell therapy group Oxford Biomedica (LSE:OXB) and US genetic medicines company Homology Medicines (Nasdaq: FIXX) have agreed to establish a high-performing, full scope adeno-associated virus (AAV) manufacturing and innovation business in the USA.

As a result of the agreement, which is immediately accretive to the group’s revenue growth with contribution from Homology and future customer pipeline, Oxford Biomedica will establish a presence in the USA and will offer global pharma and biotech clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies.

Oxford Biomedica takes 80% stake

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK